Navigation Links
EpiCept Reports Second Quarter 2013 Operating and Financial Results
Date:7/31/2013

rical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that we may be unable to complete the proposed merger transaction with Immune Pharmaceuticals Ltd.; the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; the risks associated with our ability to continue to meet our obligations under our existing debt agreements; the risk that clinical trials for AmiKet™ or crolibulin™ will not be successful; the risk that AmiKet™, Azixa® or crolibulin™ will not receive regulatory approval or achieve significant commercial success; the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet™ on attractive terms, a timely basis or at all; the risk that Ceplene® will not receive regulatory approval or marketing authorization in the United States or Canada; the risk that Ceplene® will not achieve significant commercial success; the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later-stage clinical trials; the risk that we will not obtain approval to market any of our product candidates; the risks associated with dependence upon key personnel; the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual
'/>"/>
SOURCE EpiCept Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
2. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
3. Interleukin Genetics Reports Third Quarter 2011 Financial Results
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
6. Pharmasset Reports Fiscal Year End 2011 Financial Results
7. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
8. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
9. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
10. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
11. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... Boston, MA (PRWEB) April 28, 2015 ... the science of the little-known and incurable disease, ... awarded $485,840 in grants to new projects in the ... and children around the world. , The FSH Society’s ... proposals for the grants. They awarded monies to projects ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 CargoSense, ... company focused on supply chain logistics, today announced ... its seed round, bringing total investment proceeds to ... early stage venture capital firms IrishAngels and Middleburg ... Innovative Technology, also participated in the round. ...
(Date:4/28/2015)... April 28, 2015 Pittcon ... the upcoming Labroots virtual event, Genetics ... The theme of this conference is a ... as RNAi, Next-generation sequencing, cancer research, sequencing, ... genomic medicine, human Genome structural variation, pharmacogenetics, ...
(Date:4/28/2015)... Showcasing continued leadership in the direct ... that provides scientifically advanced, age-defying products, has been ... Association (DSA) by the DSA Board of Directors. ... the DSA confirmed that Nerium’s business practices are ... association: to ensure that direct sales consumers and ...
Breaking Biology Technology:FSH Society Awards $485,000 in Grants for Research Dedicated to FSH Muscular Dystrophy 2FSH Society Awards $485,000 in Grants for Research Dedicated to FSH Muscular Dystrophy 3FSH Society Awards $485,000 in Grants for Research Dedicated to FSH Muscular Dystrophy 4CargoSense Completes Seed Round Offering By Raising $2.5 Million 2CargoSense Completes Seed Round Offering By Raising $2.5 Million 3CargoSense Completes Seed Round Offering By Raising $2.5 Million 4Pittcon Announces Plans to Exhibit at the Annual Labroots Genetics and Genomics Virtual Event 2Pittcon Announces Plans to Exhibit at the Annual Labroots Genetics and Genomics Virtual Event 3Nerium International Receives Direct Selling Association Membership 2Nerium International Receives Direct Selling Association Membership 3
... at American Society of Pharmacognosy, EMERYVILLE, Calif., ... will present seminal information on a new drug ... 7th Annual Oxford International,Conference on the Science of ... April 12-16, 2008. Scott Baggett, Ph.D., a member ...
... April 14 Codexis, Inc. announced,today that it has ... U.S.,Securities and Exchange Commission ("SEC") relating to the proposed ... of the Codexis,registration statement on Form S-1 can be ... shares being offered and the price,range for the offering ...
... and reduced cost for ... pharmaceutical manufacturers, NEW YORK, ... agreement with Chiral Quest, Inc., a manufacturer and,developer of chiral ... chiral products to the pharmaceutical industry., Effective immediately, Sumitomo ...
Cached Biology Technology:Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness 2Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness 3Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering 2Sumitomo Corporation of America Named Exclusive Distribution and Sales Agent for Chiral Quest 2
(Date:4/27/2015)... April 27, 2015  For more than four decades, ... has been the premier worldwide event for the unmanned ... a must-attend event for any local, national, or trade ... emerging commercial markets and current applications of unmanned technologies. ... this projected $48 billion industry, and how it will ...
(Date:4/27/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... the first week of May, 2015 and will be ... Gino Pereira , Chief Executive ... company as Wocket® enters the consumer market. We would ...
(Date:4/27/2015)... Apr. 27, 2015 Profile Solutions, Inc. (OTC: ... security systems is pleased to announce that Dr ... consultant and member of its scientific advisory board. ... as a thought leader in technology-enhanced learning models. He ... and has published studies and books focused on online ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... of Standards and Technology (NIST) will no longer provide ... mercury thermometer calibration program marks the end of an ... the doors opened in 1901. The closing of the ... with the U.S. Environmental Protection Agency (EPA) and a ...
... French . Clostridium difficile ... and other health care facilities, but no new drugs to ... a large-scale, phase 3 trial conducted by Canadian and U.S. ... existing treatments, demonstrating a 45 percent reduction in recurrences vs. ...
... , This release is available in German . ... and is extremely precise: within a few seconds, a laser beam ... screws, clamps or glues whatsoever. The result is a perfect weld ... or particles flying through the air during welding. What,s more: the ...
Cached Biology News:End of an era: NIST to cease calibrating mercury thermometers 2First new C. difficile drug in a generation superior to existing treatments: Researchers 2Laser welding in the right light 2
... Agencourt AMPure is a magnetic ... requires no sample transfer, centrifugation ... purifies small and large PCR ... 384-well microplates. Agencourt AMPure can ...
... Agencourt AMPure is a magnetic ... requires no sample transfer, centrifugation ... purifies small and large PCR ... 384-well microplates. Agencourt AMPure can ...
... efficient enrichment of functional endoplasmic reticulum ... culture. The isolated ER are useful ... pathway analysis. Metabolic abnornalities of ER ... cystic fibrosis and many more ER ...
Blasticidin resistance gene (bsr), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
Biology Products: